Nexthera Capital LP increased its position in Pfizer, Inc. (NYSE:PFE) by 146.8% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 785,051 shares of the biopharmaceutical company’s stock after buying an additional 467,000 shares during the period. Pfizer comprises approximately 13.7% of Nexthera Capital LP’s portfolio, making the stock its largest position. Nexthera Capital LP’s holdings in Pfizer were worth $26,857,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Pfizer during the fourth quarter worth $1,896,890,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Pfizer during the fourth quarter worth $289,666,000. Appaloosa LP bought a new stake in shares of Pfizer during the fourth quarter worth $156,229,000. I.G. Investment Management LTD. boosted its stake in shares of Pfizer by 24.7% in the fourth quarter. I.G. Investment Management LTD. now owns 11,087,884 shares of the biopharmaceutical company’s stock worth $360,134,000 after buying an additional 2,194,738 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Pfizer by 8.2% in the fourth quarter. Macquarie Group Ltd. now owns 24,455,341 shares of the biopharmaceutical company’s stock worth $794,310,000 after buying an additional 1,845,343 shares in the last quarter. 70.10% of the stock is owned by institutional investors.

Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.51% during trading on Friday, reaching $33.25. The company had a trading volume of 12,928,473 shares. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.38. The firm has a 50 day moving average price of $33.40 and a 200 day moving average price of $33.31. The company has a market cap of $198.43 billion, a price-to-earnings ratio of 24.32 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. Analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.85%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

TRADEMARK VIOLATION NOTICE: “Nexthera Capital LP Has $26.86 Million Stake in Pfizer, Inc. (PFE)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://theolympiareport.com/2017/08/12/nexthera-capital-lp-has-26-86-million-stake-in-pfizer-inc-pfe.html.

A number of analysts have weighed in on PFE shares. Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Barclays PLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. Sanford C. Bernstein reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. BMO Capital Markets reaffirmed a “hold” rating and issued a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Finally, Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $37.77.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.